Steven M Horwitz

28PUBLICATIONS

227CO-AUTHORS

Haematological tumoursPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)Molecular targetsSolid tumours

Get your video featured.

Publish with JoVE

Get your video featured.

Publish with JoVE

Publications (28)

Sort by Publication Date:

|Jun 29, 2026

Extranodal natural killer/T-cell lymphoma: From fatal to curable.

|Apr 29, 2026

Integrative Molecular Analysis Reveals Determinants of Clinical Outcomes in <i>TP53</i>-Mutated Diffuse Large B-Cell Lymphoma.

|Apr 22, 2026

Duvelisib Induces Deep Responses in Peripheral T-Cell Lymphoma: Final Results of the Phase II PRIMO Trial of Duvelisib in Relapsed/Refractory Peripheral T-Cell Lymphoma.

|Jan 28, 2026

Correction: Brentuximab vedotin plus chemotherapy for the treatment of front-line systemic anaplastic large cell lymphoma: subgroup analysis of the ECHELON-2 study at 5 years' follow-up.

Eva Domingo-Domènech, Barbara Pro, Tim Illidge

|Oct 28, 2025

Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma.

Masaya Tachibana, Steven Horwitz, Eric Jacobsen

|Aug 29, 2025

Treatment outcomes and CNS relapse risk in patients with primary cutaneous DLBCL, leg-type in the rituximab era.

Giulio Cassanello, Esther Drill, Annie Qiu

Pageof 5

Frequent Collaborators

Maria Lia Palomba

Gilles Salles

Andrew D Zelenetz

Ahmet Dogan

Santosha Vardhana

Esther Drill

Matthew J Matasar

Pier Luigi Zinzani

Alison J Moskowitz

Anita Kumar

Frequent Collaborators

Maria Lia Palomba

Gilles Salles

Andrew D Zelenetz

Ahmet Dogan